A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Apimostinel (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 22 Jan 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2020, as reported by ClinicalTrials.gov.
- 22 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 16 Nov 2015 New trial record